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www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMBackground: The frequency and prognostic impact of bleeding after hospital
discharge for PCI has not been well studied. We sought to identify the incidence,
predictors and prognostic impact of post-discharge bleeding (PDB) after percutaneous
coronary intervention (PCI) at 2 years.
Methods: ADAPT-DES was a prospective, multicenter registry of patients success-
fully treated with one or more drug-eluting stents. Patients were stratiﬁed and 2-year
outcomes according to the occurrence of PDB.
Results: Among 8,582 patients who underwent PCI in ADAPT-DES, PDB occurred in
610/8,577 hospital survivors (7.1%) at median time of 210 [17, 453] days after the index
procedure. Gastrointestinal bleeding (n¼208; 34.1%) was the most frequent type of PDB.
Independent predictors of PDB were in-hospital bleeding (HR [95%CI] ¼ 12.27
[9.92,15.16], P< 0.0001), warfarin use at discharge (HR [95%CI] ¼ 1.60 [1.23, 2.09],
P¼0.0005), presence of coronary calciﬁcation (HR [95%CI] ¼ 1.27 [1.06, 1.51],
P¼0.008), lower creatinine clearance (HR [95%CI] ¼ 1.04 [1.02, 1.07], P¼0.002), pe-
ripheral arterial disease (HR [95%CI]¼ 1.40 [1.13, 1.75], P¼0.003), andVerifyNowPRU
208 (HR [95%CI] ¼ 1.20 [1.01, 1.43], P¼0.03). PDB was strongly associated with 2-
year adverse outcomes (Table). By multivariable analysis, including the occurrence of
myocardial infarctionpost-discharge as a time-dependent co-variable, PDBwas a powerful
independent predictor of 2-year mortality (HR [95%CI]¼ 3.91 [2.90, 5.27], P< 0.0001).
Conclusions: PDB after DES occurs within 2 years in w1 in 14 patients, and is
strongly predictive of long-term mortality.Table 2. Two-year Outcomes According to Post-discharge Bleeding
Post-discharge Bleeding
(n¼610)
No Post-discharge Bleeding
(n¼7967) P-value
Death 70 (11.8) 241 (3.2) <0.0001
Cardiovascular 39 (6.8) 154 (2.1) <0.0001
Non-cardiovascular 31 (5.3) 87 (1.2) <0.0001
Myocardial infarction 60 (10.7) 209 (2.8) <0.0001
Q-wave 8 (1.4) 38 (0.5) 0.006
Non Q-wave 52 (9.3) 176 (2.4) <0.0001
Deﬁnite /probable ST 8 (1.4) 76 (1.0) 0.38
Major adverse cardiac
events
124 (21.5) 645 (8.5) <0.0001
Target vessel failure 195 (32.6) 968 (12.8) <0.0001
Data presented as n (%); major adverse cardiac events is a composite of cardiac death,
myocardial infarction or target lesion revascularization; Target vessel failure is a composite of
death, myocardial infarction and target vessel revascularization; ST¼stent thrombosis
Table 1. Freedom from 1-year MACE: ORBIT II Males vs Females
Males Females p-value
Freedom from MACE (%) 83.5 83.8 0.88
Freedom from cardiac death (%) 96.1 98.7 0.15
Freedom from MI (%) 89.9 91.1 0.67
Freedom from Q-wave MI (%) 99.0 99.3 0.67
Freedom from Non-Q-wave MI (%) 90.9 91.7 0.77
Freedom from TVR/TLR (%) 94.6 93.3 0.61
MACE: major adverse cardiac events; MI: myocardial infarction; TVR: target vessel revascu-
larization; TLR: target lesion revascularization
p-values from Cox Proportional Hazards ModelAtherectomy and Plaque Modiﬁcation
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Background: Percutaneous coronary intervention (PCI) in elderly patients is associated
with higher rates of complications and worse short term prognosis. This may be due to
increased co-morbidities including renal disease, tortuous vascular anatomy, and
calciﬁed arteries. For these reasons, elderly patients are excluded from many clinical
trials, leading to a paucity of evidence to determine optimal therapy for these patients. In
this analysis, we evaluate the 1-year outcomes of elderly patients in the ORBIT II Trial.
Methods: ORBIT II (443 patients, 49 US sites) is the ﬁrst prospective trial to
exclusively study patients with severely calciﬁed coronary lesions. The Diamondback
360 Coronary Orbital Atherectomy System (OAS) (Cardiovascular Systems, Inc.,
St. Paul, MN) was used to modify and prepare lesions prior to stent placement. The
major adverse cardiac event (MACE) rate was examined at one-year in patients
75 years of age (N¼174) and < 75 years of age (N¼269).
Results: Patients 75 years of age were more likely to be former smokers, have lower
eGFR at baseline, lower body mass index at baseline, as well as higher prevalence of
history of hypertension and stroke. The total length of calcium in patients 75 years
of age was longer compared to patients < 75 years of age (30.6  1.3 mm vs. 27.1 
1.0 mm, p¼0.01). As estimated by Kaplan Meier at 1-year, patients 75 years of ageJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Atand patients < 75 years of age had similar high freedom from MACE (82.7% vs.
84.2%, p¼0.67), myocardial infarction (MI) (89.1% vs. 91.1%, p¼0.50), non-Q-wave
MI (89.7% vs. 92.2%, p¼0.37), Q-wave MI (99.4% vs. 98.9%, p¼0.56), target vessel
revascularization/target lesion revascularization (TVR/TLR) (94.1% vs. 94.2%,
p¼0.97) and cardiac death (97.1% vs. 96.9%, p¼0.93).
Conclusions: Despite more complex lesions elderly patients with severely calciﬁed
coronary arteries had similar outcomes compared to younger patients when treated
with the Diamondback 360 Coronary OAS to facilitate stent delivery.
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Background: A negative correlation between female gender and some in-hospital
adverse events after percutaneous coronary intervention (PCI) has been reported. In
this analysis, we evaluate the 1-year outcomes of male and female patients in the
ORBIT II Trial.
Methods: The prospective ORBIT II Trial enrolled 443 patients at 49 sites in the U.S.
and patients were treated with the Diamondback 360 Coronary Orbital Atherectomy
System (OAS) (Cardiovascular Systems, Inc., St. Paul, MN) to prepare de novo,
severely calciﬁed coronary lesions for stent placement. In this analysis, the 1-year
major adverse cardiac event (MACE) rate, deﬁned as myocardial infarction (MI),
cardiac death, and target vessel revascularization (TVR) was evaluated in male
(N¼286) and female (N¼157) ORBIT II patients as estimated by Kaplan-Meier.
Results: At baseline compared to males, females were older (73.3  0.8 vs 70.4 
0.6, p¼0.001) and had lower mean eGFR (71.3  2.1 vs 78.2  1.5, p¼0.002). Males
had a higher rate of previous coronary artery bypass graft (18.2% vs 8.3%, p¼0.005).
The rate of successful stent delivery (96.8% vs 99.4%, p¼0.11) and < 50% residual
stenosis (98.2% vs 99.4%, p¼0.43) was similar in males and females, respectively. As
shown in Table 1, both males and females had high freedom from 1-year MACE.Conclusions: Preparation of severely calciﬁed coronary lesions with the Diamond-
back 360 Coronary OAS to facilitate stent deployment results in high rates of freedom
from 1-year MACE, irrespective of gender.
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Background: Rotational atherectomy (RA) is an effective way to mechanically
debulk heavily calciﬁed lesions before stenting. We sought to identify procedural
factors associated with long term cardiovascular outcome.
Methods: Retrospective evaluation of all patients who underwent RA and PCI in three
large UK tertiary cardiac centres (Leeds General Inﬁrmary, Royal Inﬁrmary of
Edinburgh and University Hospital of North Staffordshire) from 14/3/2005 to
18/1/2013. MACE was deﬁned as cardiac death, MI and TVR.
Results: 518 patients (mean age 71.5+/-9.3yrs) had RA with mean follow-up 27.6+/-
17.3 months. 68.3% were male, 28.7% had diabetes mellitus (DM) and 34.6% were
treated because of ACS. 974 stents were implanted in 97.3% of the cases
(75.9% DES). 30.7% performed transradially and 32.7% used a GP IIb/IIIa inhibitor.
Maximum burr size was 1.75mm in 85.5% of patients; mean SYNTAX score
19.5+/-11.6. Procedural complications occurred in 6.3% patients and vascular com-
plications in 2.1%. Outcomes in the follow up period were: MACE 18.7%, all-cause
death 13.7%, cardiac death 6.6%, MI 11.2%, TVR 7.5%, deﬁnite stent thrombosis
(ST) 1.2% and stroke 2.9%. Patients with intermediate and high syntax scores (>22
and >32) were more likely to have an MI, ST, MACE, cardiac death or death from
any cause (table 1). Patients with a syntax score >32 were more likely to have aherectomy and Plaque Modiﬁcation B39
